HRP20241526T1 - Stabilni višedozni pripravci, koji sadrže protutijelo i konzervans - Google Patents
Stabilni višedozni pripravci, koji sadrže protutijelo i konzervans Download PDFInfo
- Publication number
- HRP20241526T1 HRP20241526T1 HRP20241526TT HRP20241526T HRP20241526T1 HR P20241526 T1 HRP20241526 T1 HR P20241526T1 HR P20241526T T HRP20241526T T HR P20241526TT HR P20241526 T HRP20241526 T HR P20241526T HR P20241526 T1 HRP20241526 T1 HR P20241526T1
- Authority
- HR
- Croatia
- Prior art keywords
- composition according
- stable
- antibody
- salt
- chloride
- Prior art date
Links
- 239000003755 preservative agent Substances 0.000 title claims 2
- 230000002335 preservative effect Effects 0.000 title claims 2
- 238000002360 preparation method Methods 0.000 title 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 2
- 229930006000 Sucrose Natural products 0.000 claims 2
- 229960003589 arginine hydrochloride Drugs 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 239000005720 sucrose Substances 0.000 claims 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims 1
- 206010053567 Coagulopathies Diseases 0.000 claims 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 235000019270 ammonium chloride Nutrition 0.000 claims 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims 1
- 235000011130 ammonium sulphate Nutrition 0.000 claims 1
- SOIFLUNRINLCBN-UHFFFAOYSA-N ammonium thiocyanate Chemical compound [NH4+].[S-]C#N SOIFLUNRINLCBN-UHFFFAOYSA-N 0.000 claims 1
- 208000015294 blood coagulation disease Diseases 0.000 claims 1
- 239000001110 calcium chloride Substances 0.000 claims 1
- 229910001628 calcium chloride Inorganic materials 0.000 claims 1
- 235000011148 calcium chloride Nutrition 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 229910001629 magnesium chloride Inorganic materials 0.000 claims 1
- 239000001632 sodium acetate Substances 0.000 claims 1
- 235000017281 sodium acetate Nutrition 0.000 claims 1
- VGTPCRGMBIAPIM-UHFFFAOYSA-M sodium thiocyanate Chemical compound [Na+].[S-]C#N VGTPCRGMBIAPIM-UHFFFAOYSA-M 0.000 claims 1
- 125000000185 sucrose group Chemical group 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 239000011592 zinc chloride Substances 0.000 claims 1
- 235000005074 zinc chloride Nutrition 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10164298 | 2010-05-28 | ||
| US35152210P | 2010-06-04 | 2010-06-04 | |
| EP11721544.2A EP2575761B1 (en) | 2010-05-28 | 2011-05-26 | Stable multi-dose compositions comprising an antibody and a preservative |
| PCT/EP2011/058648 WO2011147921A1 (en) | 2010-05-28 | 2011-05-26 | Stable multi-dose compositions comprising an antibody and a preservative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20241526T1 true HRP20241526T1 (hr) | 2025-01-03 |
Family
ID=42562357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20241526TT HRP20241526T1 (hr) | 2010-05-28 | 2011-05-26 | Stabilni višedozni pripravci, koji sadrže protutijelo i konzervans |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20130136733A1 (enExample) |
| EP (1) | EP2575761B1 (enExample) |
| JP (3) | JP6294075B2 (enExample) |
| KR (1) | KR20130086144A (enExample) |
| CN (2) | CN102905692B (enExample) |
| AU (1) | AU2011257219B2 (enExample) |
| BR (1) | BR112012030139A2 (enExample) |
| CA (1) | CA2800188A1 (enExample) |
| ES (1) | ES2993022T3 (enExample) |
| HR (1) | HRP20241526T1 (enExample) |
| MX (1) | MX2012013586A (enExample) |
| RS (1) | RS66182B1 (enExample) |
| RU (1) | RU2012153786A (enExample) |
| WO (1) | WO2011147921A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2646792T3 (es) | 2002-01-25 | 2017-12-18 | Novo Nordisk A/S | Anticuerpos monoclonales contra bucles extracelulares de C5aR |
| CA2714296A1 (en) | 2008-02-20 | 2009-08-27 | G2 Inflammation Pty Ltd | Humanized anti-c5ar antibodies |
| WO2010000721A1 (en) | 2008-06-30 | 2010-01-07 | Novo Nordisk A/S | Anti-human interleukin-20 antibodies |
| US8454956B2 (en) | 2009-08-31 | 2013-06-04 | National Cheng Kung University | Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies |
| WO2011104381A2 (en) | 2010-02-26 | 2011-09-01 | Novo Nordisk A/S | Stable antibody containing compositions |
| SI3345615T1 (sl) | 2010-03-01 | 2020-03-31 | Bayer Healthcare Llc | Optimizirana monoklonska protitelesa proti zaviralcu poti tkivnega faktorja (TFPI) |
| KR20130086144A (ko) * | 2010-05-28 | 2013-07-31 | 노보 노르디스크 에이/에스 | 항체 및 보존제를 포함하는 안정한 다중-투여 조성물 |
| ES2929575T3 (es) | 2011-06-06 | 2022-11-30 | Novo Nordisk As | Anticuerpos terapéuticos |
| ES2732243T3 (es) * | 2012-02-16 | 2019-11-21 | Santarus Inc | Composiciones farmacéuticas de anticuerpos ANTI-VLA1 (CD49A) |
| HK1204990A1 (en) * | 2012-03-26 | 2015-12-11 | Sanofi | Stable igg4 binding agent formulations |
| US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
| US20140004131A1 (en) * | 2012-05-04 | 2014-01-02 | Novartis Ag | Antibody formulation |
| WO2014015133A1 (en) | 2012-07-19 | 2014-01-23 | National Cheng Kung University | Treatment of osteoarthritis using il-20 antagonists |
| US8603470B1 (en) | 2012-08-07 | 2013-12-10 | National Cheng Kung University | Use of IL-20 antagonists for treating liver diseases |
| US8852588B2 (en) | 2012-08-07 | 2014-10-07 | National Cheng Kung University | Treating allergic airway disorders using anti-IL-20 receptor antibodies |
| US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| TWI694836B (zh) | 2014-05-16 | 2020-06-01 | 英商葛蘭素史克智慧財產管理有限公司 | 抗體調配物 |
| CN114163531B (zh) | 2015-08-19 | 2025-06-13 | 辉瑞公司 | 组织因子途径抑制剂抗体及其用途 |
| CN110913904A (zh) * | 2017-05-05 | 2020-03-24 | 美国安进公司 | 用于改善的储存和施用的包含双特异性抗体构建体的药物组合物 |
| JP2022500414A (ja) | 2018-09-12 | 2022-01-04 | シルバーバック セラピューティックス インコーポレイテッド | 免疫刺激性コンジュゲートにより疾患を処置する方法および組成物 |
| KR102337683B1 (ko) | 2018-09-21 | 2021-12-13 | 주식회사 녹십자 | 고효율 항-tfpi 항체 조성물 |
| KR20220035908A (ko) | 2019-06-19 | 2022-03-22 | 실버백 테라퓨틱스, 인크. | 항-메소텔린 항체 및 이의 면역접합체 |
| WO2021094917A1 (en) * | 2019-11-13 | 2021-05-20 | Pfizer Inc. | Stable aqueous anti-tfpi antibody formulation |
| JP7735291B2 (ja) | 2020-02-21 | 2025-09-08 | エーアールエス ファーマシューティカルズ、インコーポレイテッド | ネクチン－４抗体コンジュゲートおよびその使用 |
| WO2022006327A1 (en) | 2020-07-01 | 2022-01-06 | Silverback Therapeutics, Inc. | Anti-asgr1 antibody conjugates and uses thereof |
| KR20230045075A (ko) | 2020-08-12 | 2023-04-04 | 이나뜨 파르마 에스.에이. | 아브도랄리맙을 사용한 피하 항-C5aR 길항제 치료 용법 |
| CN116390715A (zh) * | 2020-09-24 | 2023-07-04 | 诺和诺德医疗保健公司 | 康赛珠单抗的药物制剂及其制备方法 |
| CN112244025A (zh) * | 2020-11-27 | 2021-01-22 | 上海创宏生物科技有限公司 | 大分子蛋白和/或核酸用无菌处理剂及其制备方法和应用 |
| KR20250093372A (ko) * | 2022-10-26 | 2025-06-24 | 니혼 메디피직스 가부시키가이샤 | 방사성 의약 조성물 |
| AU2024265540A1 (en) * | 2023-05-01 | 2025-10-30 | Regeneron Pharmaceuticals, Inc. | Multidose antibody drug products using phenol or benzyl alcohol |
Family Cites Families (127)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5567584A (en) | 1988-01-22 | 1996-10-22 | Zymogenetics, Inc. | Methods of using biologically active dimerized polypeptide fusions to detect PDGF |
| US20020099179A1 (en) | 1989-12-21 | 2002-07-25 | Linda K. Jolliffe | Cdr-grafted antibodies |
| DK261490D0 (da) | 1990-10-31 | 1990-10-31 | Novo Nordisk As | New pharmaceutical compound |
| US6165467A (en) | 1991-07-20 | 2000-12-26 | Yoshihide Hagiwara | Stabilized human monoclonal antibody preparation |
| US5789192A (en) | 1992-12-10 | 1998-08-04 | Schering Corporation | Mammalian receptors for interleukin-10 (IL-10) |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| JP3681206B2 (ja) | 1995-12-26 | 2005-08-10 | 株式会社三菱化学ヤトロン | 抗ファクターＸａ・ティシュファクターパスウェイインヒビター複合体モノクローナル抗体及びその使用 |
| US6084248A (en) | 1996-06-28 | 2000-07-04 | Seiko Epson Corporation | Thin film transistor, manufacturing method thereof, and circuit and liquid crystal display device using the thin film transistor |
| EP2065396A1 (en) | 1996-08-30 | 2009-06-03 | Human Genome Sciences, Inc. | Interleukin-19 |
| US5985614A (en) | 1996-08-30 | 1999-11-16 | Human Genome Sciences, Inc. | Polynucleotides encoding interleukin-19 |
| WO1999046281A2 (en) | 1998-03-10 | 1999-09-16 | Genentech, Inc. | Novel polypeptides and nucleic acids encoding the same |
| US5945511A (en) | 1997-02-20 | 1999-08-31 | Zymogenetics, Inc. | Class II cytokine receptor |
| WO1998048837A1 (en) | 1997-04-30 | 1998-11-05 | Enzon, Inc. | Polyalkylene oxide-modified single chain polypeptides |
| WO1999003982A1 (en) | 1997-07-16 | 1999-01-28 | Human Genome Sciences, Inc. | Interleukin-20 |
| US6486301B1 (en) | 1997-07-16 | 2002-11-26 | Human Genome Sciences, Inc. | Interleukin-20 |
| JP2001512668A (ja) | 1997-08-06 | 2001-08-28 | ザイモジェネティクス，インコーポレイティド | リポカリン相同体 |
| US6576743B1 (en) | 1997-11-26 | 2003-06-10 | Zymogenetics, Inc. | Mammalian cytokine-like polypeptide-10 |
| PT1047781E (pt) | 1998-01-23 | 2004-11-30 | Immunex Corp | Receptores de il-18 |
| CA2323236A1 (en) | 1998-03-09 | 1999-09-16 | Schering Corporation | Human receptor proteins; related reagents and methods |
| US7198789B2 (en) | 1998-03-17 | 2007-04-03 | Genetics Institute, Llc | Methods and compositions for modulating interleukin-21 receptor activity |
| CN1233476A (zh) | 1998-04-24 | 1999-11-03 | 陆道培 | 治疗急性白血病的药物及其制备方法 |
| WO1999061630A2 (en) | 1998-05-26 | 1999-12-02 | Regeneron Pharmaceuticals, Inc. | Chimeric molecules comprising an extracellular ligand binding domain of a receptor and an ige fc or constant region, and their use in an assay system |
| AU4411699A (en) | 1998-06-05 | 1999-12-20 | Human Genome Sciences, Inc. | Interferon receptor hkaef92 |
| US7034123B2 (en) | 1998-09-01 | 2006-04-25 | Genetech, Inc. | Anti-PRO1347 antibodies |
| JP2002524514A (ja) * | 1998-09-17 | 2002-08-06 | イーライ・リリー・アンド・カンパニー | タンパク質製剤 |
| US7087215B2 (en) * | 1998-12-21 | 2006-08-08 | Generex Pharmaceuticals Incorporated | Methods of administering and enhancing absorption of pharmaceutical agents |
| US6451286B1 (en) * | 1998-12-21 | 2002-09-17 | Generex Pharmaceuticals Incorporated | Pharmaceutical compositions for buccal and pulmonary administration comprising an alkali metal alkyl sulfate and at least three micelle-forming compounds |
| EP1141008A1 (en) | 1998-12-31 | 2001-10-10 | Millennium Pharmaceuticals, Inc. | Class ii cytokine receptor-like proteins and nucleic acids encoding them |
| JP2004522402A (ja) | 1999-06-02 | 2004-07-29 | ジェネンテック・インコーポレーテッド | 同一のものをコードする分泌及び膜貫通ポリペプチドと核酸 |
| US20050060101A1 (en) | 1999-06-28 | 2005-03-17 | Bevilacqua Michael P. | Systems and methods for characterizing a biological condition or agent using precision gene expression profiles |
| WO2001024814A1 (en) | 1999-10-04 | 2001-04-12 | Chiron Corporation | Stabilized liquid polypeptide-containing pharmaceutical compositions |
| KR100399156B1 (ko) * | 1999-11-19 | 2003-09-26 | 주식회사 엘지생명과학 | α-인터페론의 용액제형 |
| US6610286B2 (en) | 1999-12-23 | 2003-08-26 | Zymogenetics, Inc. | Method for treating inflammation using soluble receptors to interleukin-20 |
| EP1246846B1 (en) | 1999-12-23 | 2008-09-10 | ZymoGenetics, Inc. | Soluble interleukin-20 receptor |
| AU2001251336B2 (en) | 2000-04-07 | 2006-09-14 | Signal Coordinating Therapy, Inc. | Methods and compositions for treating neoplasms |
| US7015194B2 (en) | 2000-05-10 | 2006-03-21 | Novo Nordisk A/S | Pharmaceutical composition comprising factor VIIa and anti-TFPI |
| JP5490972B2 (ja) | 2000-08-04 | 2014-05-14 | 中外製薬株式会社 | タンパク質注射製剤 |
| CA2418950A1 (en) | 2000-08-08 | 2002-02-14 | Zymogenetics, Inc. | Soluble zcytor 11 cytokine receptors |
| ES2644275T3 (es) | 2000-08-11 | 2017-11-28 | Chugai Seiyaku Kabushiki Kaisha | Preparaciones estabilizadas que contienen anticuerpos |
| US6875432B2 (en) | 2000-10-12 | 2005-04-05 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
| US7101539B2 (en) | 2001-02-28 | 2006-09-05 | Eli Lilly And Company | Use of LP82 to treat hematopoietic disorders |
| ATE432942T1 (de) | 2001-03-09 | 2009-06-15 | Zymogenetics Inc | Löslicher heterodimerer cytokinrezeptor |
| ATE454137T1 (de) | 2001-07-25 | 2010-01-15 | Facet Biotech Corp | Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab |
| WO2003028630A2 (en) | 2001-10-04 | 2003-04-10 | Genetics Institute Llc. | Methods and compositions for modulating interleukin-21 receptor activity |
| US7022289B1 (en) | 2001-10-10 | 2006-04-04 | The United States Of America As Represented By The Secretary Of The Army | Chemical and biological sampling device and kit and method of use thereof |
| IL161968A0 (en) * | 2001-11-14 | 2005-11-20 | Centocor Inc | Anti-il-6 antibodies, compositions, methods and uses |
| ATE521361T1 (de) | 2001-12-17 | 2011-09-15 | Zymogenetics Inc | Verfahren zur behandlung von gebärmutterhalskrebs |
| JP3792698B2 (ja) | 2002-02-14 | 2006-07-05 | 中外製薬株式会社 | 抗体含有溶液製剤 |
| DE60322513D1 (de) | 2002-02-27 | 2008-09-11 | Immunex Corp | Stabilisierte TNFR-Fc Formulierung mit Arginin |
| CA2481304A1 (en) | 2002-03-27 | 2003-10-09 | Patrick Hwu | Method for treating cancer in humans |
| US20040009168A1 (en) | 2002-04-05 | 2004-01-15 | Elizabet Kaisheva | Multidose antibody formulation |
| AU2005254062B2 (en) | 2002-04-11 | 2011-02-17 | Medimmune, Llc | High pressure spray-dry of bioactive materials |
| PT1531850E (pt) | 2002-06-07 | 2012-05-07 | Zymogenetics Inc | Utilização de il-21 e anticorpo monoclonal para tratar cancros sólidos |
| US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
| US20040022792A1 (en) | 2002-06-17 | 2004-02-05 | Ralph Klinke | Method of stabilizing proteins at low pH |
| CA2490423A1 (en) | 2002-06-21 | 2003-12-31 | Biogen Idec Inc. | Buffered formulations for concentrating antibodies and methods of use thereof |
| ES2271610T3 (es) | 2002-07-18 | 2007-04-16 | Fabio Perini S.P.A. | Unidad de almacenamiento para productos alargados. |
| US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| AU2003293543A1 (en) | 2002-12-13 | 2004-07-09 | Abgenix, Inc. | System and method for stabilizing antibodies with histidine |
| PT2236154T (pt) | 2003-02-10 | 2018-06-26 | Biogen Ma Inc | Formulação de imunoglobulinas e método de preparação das mesmas |
| ES2349779T5 (es) * | 2003-04-04 | 2013-11-26 | Genentech, Inc. | Formulaciones de anticuerpos y de proteínas a concentración elevada |
| EP1648509B8 (en) | 2003-07-15 | 2012-10-24 | Amgen Inc. | Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors |
| HUE026793T2 (en) | 2003-10-01 | 2016-07-28 | Kyowa Hakko Kirin Co Ltd | A method for stabilizing an antibody and a stabilized solution-type antibody preparation |
| EP1712240B1 (en) | 2003-12-25 | 2015-09-09 | Kyowa Hakko Kirin Co., Ltd. | Stable water-based medicinal preparation containing antibody |
| DK1812476T3 (da) | 2004-10-22 | 2010-10-25 | Zymogenetics Inc | Anti-IL-22RA-antistoffer og bindingspartnere samt fremgangsmåder til anvendelse ved inflammation |
| JP2008532931A (ja) | 2005-02-08 | 2008-08-21 | ザイモジェネティクス， インコーポレイテッド | 抗ｉｌ−２０、抗ｉｌ−２２および抗ｉｌ−２２ｒａ抗体ならびに結合パートナー、ならびに炎症における使用法 |
| US7525604B2 (en) | 2005-03-15 | 2009-04-28 | Naxellent, Llc | Windows with electrically controllable transmission and reflection |
| ATE501248T1 (de) | 2005-07-02 | 2011-03-15 | Arecor Ltd | Stabile wässrige systeme mit proteinen |
| WO2007006858A2 (en) | 2005-07-12 | 2007-01-18 | Oy Jurilab Ltd | Method for treatment of cardiovascular and metabolic diseases and detecting the risk of the same |
| CA2618068C (en) | 2005-08-05 | 2016-02-16 | Amgen Inc. | Stable aqueous protein or antibody pharmaceutical formulations and their preparation |
| EP1945814A2 (en) | 2005-09-27 | 2008-07-23 | Source MDX | Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis |
| WO2007038501A2 (en) | 2005-09-27 | 2007-04-05 | The Feinstein Institute For Medical Research | Rheumatoid arthritis markers |
| CN104984352A (zh) | 2005-11-21 | 2015-10-21 | 圣诺菲·帕斯图尔有限公司 | 重组病毒的稳定制剂 |
| EP1962907A2 (en) | 2005-12-21 | 2008-09-03 | Wyeth a Corporation of the State of Delaware | Protein formulations with reduced viscosity and uses thereof |
| US9084777B2 (en) | 2005-12-28 | 2015-07-21 | Chugai Seiyaku Kabushiki Kaisha | Stabilized antibody-containing formulations |
| KR20080098504A (ko) | 2006-02-03 | 2008-11-10 | 메디뮨 엘엘씨 | 단백질 제제 |
| DE102006005094A1 (de) | 2006-02-04 | 2007-08-09 | Degussa Gmbh | Titandioxid und Polycarboxylatether enthaltende Dispersion |
| TW200744634A (en) | 2006-02-21 | 2007-12-16 | Wyeth Corp | Methods of using antibodies against human IL-22 |
| WO2007105133A2 (en) | 2006-03-15 | 2007-09-20 | Koninklijke Philips Electronics N.V. | Remote control pointing technology with roll detection |
| TW200806317A (en) | 2006-03-20 | 2008-02-01 | Wyeth Corp | Methods for reducing protein aggregation |
| JP4294082B2 (ja) | 2006-03-23 | 2009-07-08 | 協和発酵キリン株式会社 | ヒトトロンボポエチン受容体に対するアゴニスト抗体 |
| EP1998806A1 (en) * | 2006-03-28 | 2008-12-10 | F. Hoffmann-Roche AG | Anti-igf-1r human monoclonal antibody formulation |
| EP1857559A1 (en) | 2006-05-16 | 2007-11-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A method for predicting responsiveness to TNF alpha blocking agents |
| JP2009540015A (ja) | 2006-06-14 | 2009-11-19 | イムクローン・リミテッド・ライアビリティ・カンパニー | 抗ｅｇｆｒ抗体の凍結乾燥製剤 |
| US20080031882A1 (en) | 2006-06-19 | 2008-02-07 | Liang Spencer C | Methods of modulating IL-22 and IL-17 |
| ES2531933T3 (es) | 2006-06-30 | 2015-03-20 | Novo Nordisk A/S | Anticuerpos anti-NKG2A y usos de los mismos |
| EP2081553B1 (en) | 2006-10-06 | 2020-08-12 | Amgen Inc. | Stable antibody formulations |
| EP2076287A2 (en) | 2006-10-12 | 2009-07-08 | Wyeth | Methods and compositions with reduced opalescence |
| WO2008048986A2 (en) | 2006-10-17 | 2008-04-24 | Children's Hospital Medical Center | Gene array technique for predicting response in inflammatory bowel diseases |
| CA2668955A1 (en) | 2006-11-09 | 2008-05-15 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Method for predicting therapeutic responsiveness to tnf-alpha blocking agents |
| CL2007003583A1 (es) | 2006-12-11 | 2008-07-18 | Hoffmann La Roche | Formulacion farmaceutica estable, parenteral, del anticuerpo contra el peptido beta amiloide (abeta); y uso de la formulacion para el tratamiento de la enfermedad de alzheimer. |
| CL2008000058A1 (es) * | 2007-01-09 | 2008-05-23 | Wyeth Corp | Formulacion que comprende un anticuerpo anti-il13, un criprotector, y una solucion amortiguadora; composicion farmaceutica que la comprende; metodo para tratar un trastorno relacionado con il13; y formas farmaceuticas que la comprenden. |
| EP2132343B1 (en) | 2007-03-01 | 2012-08-29 | Université Catholique de Louvain | Method for the determination and the classification of rheumatic conditions |
| US8575751B2 (en) | 2007-03-23 | 2013-11-05 | Panasonic Corporation | Conductive bump, method for producing the same, and electronic component mounted structure |
| EP2077859A4 (en) | 2007-03-30 | 2010-11-24 | Medimmune Llc | ANTIBODY FORMULATION |
| GB0707938D0 (en) | 2007-04-25 | 2007-05-30 | Univ Strathclyde | Precipitation stabilising compositions |
| WO2008132176A2 (en) | 2007-04-27 | 2008-11-06 | Universite Catholique De Louvain | Method for evaluating the response of an individual to tnf blocking therapy |
| US20100303813A1 (en) | 2007-06-08 | 2010-12-02 | Biogen Idec Ma Inc. | Biomarkers for predicting anti-tnf responsiveness or non-responsiveness |
| US20090208492A1 (en) | 2007-06-14 | 2009-08-20 | Elan Pharmaceuticals, Inc. | Lyophilized Immunoglobulin Formulations and Methods of Preparation |
| PT2170390T (pt) | 2007-06-14 | 2019-02-12 | Biogen Ma Inc | Formulações com anticorpo natalizumab |
| US20090004189A1 (en) | 2007-06-18 | 2009-01-01 | Genentech, Inc. | Biological markers predictive of rheumatoid arthritis response to b-cell antagonists |
| AU2008269086B2 (en) | 2007-06-25 | 2014-06-12 | Amgen Inc. | Compositions of specific binding agents to hepatocyte growth factor |
| UA107557C2 (xx) | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу | |
| EP2173163A4 (en) | 2007-07-06 | 2010-12-08 | Glaxosmithkline Llc | ANTIBODY FORMULATIONS |
| US20110143351A1 (en) | 2007-07-20 | 2011-06-16 | National Institute For Biopr0Essing Research And Training Limited | Glyosylation markers for cancer and chronic inflammation |
| WO2009015398A1 (en) | 2007-07-26 | 2009-01-29 | Oklahoma Medical Research Foundation | Methods for inflammatory disease management |
| US9308257B2 (en) | 2007-11-28 | 2016-04-12 | Medimmune, Llc | Protein formulation |
| CA3102679A1 (en) | 2007-12-14 | 2009-06-25 | Birgitte Urso | Antibodies against human nkg2d and uses thereof |
| CA2714296A1 (en) | 2008-02-20 | 2009-08-27 | G2 Inflammation Pty Ltd | Humanized anti-c5ar antibodies |
| WO2009120684A1 (en) | 2008-03-25 | 2009-10-01 | Medimmune, Llc | Antibody formulation |
| CN103396480A (zh) | 2008-05-15 | 2013-11-20 | 诺沃—诺迪斯克有限公司 | 抗体纯化方法 |
| TWI451876B (zh) * | 2008-06-13 | 2014-09-11 | Lilly Co Eli | 聚乙二醇化之離脯胰島素化合物 |
| WO2010000721A1 (en) | 2008-06-30 | 2010-01-07 | Novo Nordisk A/S | Anti-human interleukin-20 antibodies |
| UA112050C2 (uk) * | 2008-08-04 | 2016-07-25 | БАЄР ХЕЛСКЕР ЛЛСі | Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi) |
| JP2012501184A (ja) | 2008-08-28 | 2012-01-19 | ワイス・エルエルシー | 自己免疫疾患におけるｉｌ−２２、ｉｌ−１７、およびｉｌ−１ファミリーのサイトカインの使用 |
| KR20110047232A (ko) | 2008-09-19 | 2011-05-06 | 에프. 호프만-라 로슈 아게 | 신규한 항체 제형 |
| EP2196476A1 (en) | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
| US8361469B2 (en) | 2008-12-22 | 2013-01-29 | Novo Nordisk A/S | Antibodies against tissue factor pathway inhibitor |
| EP2414542B1 (en) | 2009-03-30 | 2017-08-30 | Tel HaShomer Medical Research Infrastructure and Services Ltd. | Methods of predicting clinical course and treating multiple sclerosis |
| EP3211094A3 (en) | 2009-09-03 | 2017-11-01 | F. Hoffmann-La Roche AG | Methods for treating, diagnosing, and monitoring rheumatoid arthritis |
| US20120208719A1 (en) | 2009-10-16 | 2012-08-16 | Mayo Foundation For Medical Education And Research | Assessing rheumatoid arthritis |
| US8580528B2 (en) | 2009-10-16 | 2013-11-12 | Stichting Vu-Vumc | Method for prognosticating the clinical response of a patient to B-lymphocyte inhibiting or depleting therapy |
| WO2011104381A2 (en) | 2010-02-26 | 2011-09-01 | Novo Nordisk A/S | Stable antibody containing compositions |
| KR20130086144A (ko) * | 2010-05-28 | 2013-07-31 | 노보 노르디스크 에이/에스 | 항체 및 보존제를 포함하는 안정한 다중-투여 조성물 |
| JP2013529089A (ja) | 2010-06-07 | 2013-07-18 | エフ．ホフマン−ラ ロシュ アーゲー | インターロイキン−６受容体を阻害するモノクローナル抗体による薬剤治療に対する応答を予測するための遺伝子発現マーカー |
| US8603470B1 (en) | 2012-08-07 | 2013-12-10 | National Cheng Kung University | Use of IL-20 antagonists for treating liver diseases |
-
2011
- 2011-05-26 KR KR1020127030515A patent/KR20130086144A/ko not_active Withdrawn
- 2011-05-26 RU RU2012153786/10A patent/RU2012153786A/ru unknown
- 2011-05-26 ES ES11721544T patent/ES2993022T3/es active Active
- 2011-05-26 CA CA2800188A patent/CA2800188A1/en not_active Withdrawn
- 2011-05-26 CN CN201180026538.4A patent/CN102905692B/zh active Active
- 2011-05-26 US US13/699,847 patent/US20130136733A1/en not_active Abandoned
- 2011-05-26 JP JP2013511686A patent/JP6294075B2/ja active Active
- 2011-05-26 MX MX2012013586A patent/MX2012013586A/es unknown
- 2011-05-26 EP EP11721544.2A patent/EP2575761B1/en active Active
- 2011-05-26 RS RS20241258A patent/RS66182B1/sr unknown
- 2011-05-26 BR BR112012030139A patent/BR112012030139A2/pt not_active IP Right Cessation
- 2011-05-26 CN CN201510485529.1A patent/CN105055306B/zh active Active
- 2011-05-26 WO PCT/EP2011/058648 patent/WO2011147921A1/en not_active Ceased
- 2011-05-26 HR HRP20241526TT patent/HRP20241526T1/hr unknown
- 2011-05-26 AU AU2011257219A patent/AU2011257219B2/en not_active Withdrawn - After Issue
-
2016
- 2016-02-09 JP JP2016022657A patent/JP6239657B2/ja active Active
-
2017
- 2017-10-31 US US15/799,276 patent/US10835602B2/en active Active
- 2017-11-01 JP JP2017211614A patent/JP6568917B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20130086144A (ko) | 2013-07-31 |
| JP2016084367A (ja) | 2016-05-19 |
| JP6294075B2 (ja) | 2018-03-14 |
| WO2011147921A1 (en) | 2011-12-01 |
| EP2575761B1 (en) | 2024-08-14 |
| AU2011257219A1 (en) | 2012-11-22 |
| CA2800188A1 (en) | 2011-12-01 |
| US10835602B2 (en) | 2020-11-17 |
| JP6239657B2 (ja) | 2017-11-29 |
| MX2012013586A (es) | 2013-01-24 |
| CN105055306A (zh) | 2015-11-18 |
| AU2011257219B2 (en) | 2014-12-04 |
| ES2993022T3 (en) | 2024-12-20 |
| JP2013527189A (ja) | 2013-06-27 |
| US20130136733A1 (en) | 2013-05-30 |
| JP2018030879A (ja) | 2018-03-01 |
| RS66182B1 (sr) | 2024-12-31 |
| EP2575761A1 (en) | 2013-04-10 |
| JP6568917B2 (ja) | 2019-08-28 |
| CN105055306B (zh) | 2019-10-01 |
| US20180104335A1 (en) | 2018-04-19 |
| CN102905692B (zh) | 2015-09-16 |
| BR112012030139A2 (pt) | 2017-06-13 |
| EP2575761C0 (en) | 2024-08-14 |
| RU2012153786A (ru) | 2014-07-10 |
| CN102905692A (zh) | 2013-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20241526T1 (hr) | Stabilni višedozni pripravci, koji sadrže protutijelo i konzervans | |
| HRP20191299T1 (hr) | Formulacije protutijela | |
| AR092470A1 (es) | Formulaciones acuosas estables de adalimumab | |
| HRP20250382T1 (hr) | Farmaceutski pripravak koji sadrži karbetocin | |
| EA201490804A1 (ru) | Препараты этанерцепта, стабилизированные хлоридом натрия | |
| HRP20160434T1 (hr) | Formulacija abeta-protutijela | |
| JP2014139241A5 (enExample) | ||
| GEP20125628B (en) | Pharmaceutical compositions containing antagonist anti-cd40 antibody | |
| EA201792552A1 (ru) | Высококонцентрированные фармацевтические композиции, содержащие антитело к cd20 | |
| RU2015132431A (ru) | Составы, содержащие антитела | |
| AR071852A1 (es) | Formulacion farmaceutica de un anticuerpo frente a ox40l | |
| MX2015015152A (es) | Formulaciones de anticuerpos biespecificos anti-il-4/anti-il-13. | |
| EA201492021A1 (ru) | Антительный состав | |
| HRP20190777T1 (hr) | Brzodjelujući pripravci inzulina | |
| EA201492292A1 (ru) | Препарат антител | |
| JP2019504086A5 (enExample) | ||
| HRP20240426T1 (hr) | Stabilni tekući farmaceutski pripravak | |
| HRP20220759T1 (hr) | Pripravci i postupci koji ih koriste za liječenje neurodegenerativne i mitohondrijske bolesti | |
| RU2017101667A (ru) | Фармацевтические композиции | |
| AR073567A1 (es) | Formulaciones de peptidos y sus usos. metodo | |
| JP2016515515A5 (enExample) | ||
| RU2019116756A (ru) | Жидкая фармацевтическая композиция | |
| JP2013524782A5 (enExample) | ||
| HRP20220011T1 (hr) | Nova stabilna formulacija za fxia protutijela | |
| RU2014102493A (ru) | Алкафтадин для применения при лечении уртикарии |